Navigation Links
Dyadic International Reports 2010 Third Quarter Financial Results
Date:11/15/2010

OFT BioACE 5X, a new acid cellulase product for the Asian textile market

Biofuels

  • Developed an improved seventh generation of a C1 biofuels strain which produces a mix of enzymes that is more efficient in releasing sugars from waste streams containing ligno-cellulosic materials than previous C1 biofuels strains
  • Initiated discussions with new potential partners and continued ongoing dialogue with companies for the potential license of Dyadic's C1 technology for the development and commercialization of biofuels and biochemicals

  • Biopharmaceuticals

  • Continued discussions with several companies and investors regarding the potential funding of EnGen Bio, Inc., Dyadic's prospective exclusive licensee of its C1 platform technology for biopharmaceutical applications, which was recently awarded a cash grant of approximately $250,000 under the U.S. Government's Qualifying Therapeutic Discovery Project program

  • Research & Development

  • Demonstrated the capability of Dyadic's C1 platform technology in third party-funded research and development projects to over-express heterologous genes for the production of certain proteins and enzymes at substantially higher levels than the original producing organism and are leveraging these results through further collaborations to improve the cost structure of new and existing products in a variety of industries
  • Continued to improve the efficiency and performance of Dyadic's enzymes for use in creating new industrial enzyme products and enhancing Dyadic's current product offerings in the areas of animal feed, pulp and paper, starch and alcohol, food and brewing, textiles and alternative fuels
  • Continued to enhance our C1 technology and mine for novel genes through the annotation project that was conducted in collaboration with Scripps Florida, a division of the Scripps Research Institute, and Dyadic Netherlands, for greater applicability in producing higher
    '/>"/>

  • SOURCE Dyadic International, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Dyadic International to Announce Third Quarter 2010 Financial Results and Hold Conference Call on November 15, 2010
    2. Dyadic International Raises $3 Million in Private Placement of Convertible Notes
    3. Dyadic International to Announce Second Quarter 2010 Financial Results and Hold Conference Call on August 13, 2010
    4. Dyadic International Announces Final Resolution and Dismissal of Stockholder Class Action Lawsuit
    5. Dyadic International Engages The Abraham Group as Strategic Advisor
    6. Dyadic International to Present at Rodman & Renshaw 6th Annual Global Healthcare Conference
    7. Dyadic International Strengthens Management Team
    8. Dyadic International Extends Collaboration With The Scripps Research Institute
    9. International Technidyne Corporation Acquired by Warburg Pincus
    10. Edwin Rivera-Martinez, Former Chief of the FDA’s International Compliance Branch, Joins PAREXEL Consulting Strategic Compliance Team
    11. Distinguished Scientist H. Mario Geysen Joins SRI International to Lead Combinatorial Sciences and Metabolic Diseases Research Programs
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/1/2015)... 1, 2015 Investor-Edge has ... Ltd (NASDAQ: GENE ), Agilent Technologies Inc. ... (NYSE: TMO ), Sequenom Inc. (NASDAQ: ... ). Free research report on Genetic Technologies can ... April 30, 2015, the NASDAQ Composite ended at ...
    (Date:5/1/2015)... RESEARCH TRIANGLE PARK, N.C. , May 1, ... today that Roger Jeffs , Ph.D., President and Co-Chief ... update on the company,s business at the Deutsche Bank 40 ... Massachusetts . The presentation will take place ... and can be accessed via a live webcast on the ...
    (Date:4/30/2015)... , April 30, 2015   Tamir Biotechnology ... today an update on its Ebola antiviral therapy program. ... leading candidates, TMR004, is currently being evaluated and considered ... the battle against Ebola. During the first quarter of ... Leadership Meeting To Accelerate The Evaluation of Potential Treatments ...
    (Date:4/30/2015)... Nitto Avecia, a leading biotechnology manufacturer and oligonucleotide ... capability to serve biotechnology pharmaceutical clients. A commitment ... to drive Nitto Avecia to enhance synthesis scale ... , In Fall 2014, Nitto Avecia first demonstrated ... Milford, MA facility, which is recognized as a ...
    Breaking Biology Technology:Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2
    ... 0641-2450-45 and 0641-2450-41;, LOTS: 107054, 117085, 047056, 097081, 107024, 107064, ... ... DEERFIELD, Ill., Jan. 25 Baxter Healthcare,Corporation has announced the voluntary recall ... vials. The company,began recalling the lots on January 17, 2008 as a ...
    ... DIEGO, Jan. 25 NuVasive, Inc. (Nasdaq:,NUVA), a medical ... treatments for the spine, announced today,details relating to its ... take place on Tuesday, February 19, 2008, after,the close ... call on Tuesday, February 19, 2008 at,5:30 p.m. ET ...
    ... 25 Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) announced ... clinical trial of a second generation oral niacin receptor ... for the,treatment of atherosclerosis and other disorders. The initiation ... "We are very pleased with the progress of this ...
    Cached Biology Technology:Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/mL 10 and 30mL Multi-Dose Vials 2NuVasive Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results 2NuVasive Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results 3Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc. 2Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc. 3
    (Date:4/13/2015)... , April 13, 2015  higi, a leading cloud-based ... to more fully engage with their communities around health ... privacy protected and secure API.  ... the most accessible, affordable, and convenient vehicle to receive ... The API will allow higi,s ...
    (Date:4/2/2015)... HAMBURG, Germany , April 2, 2015 /PRNewswire/ ... ten fingerprint tests DERMALOG by far outperforms the ... While always maintaining high accuracy, the system is ... second. Hence, the speed proves up to be ... 40% faster than its runner-up performance. ...
    (Date:4/1/2015)... , April 1, 2015   Medisafe ™, the ... users across iOS and Android ... integrating biofeedback into the platform to allow patients to ... For the first time, patients will be able to ... dose impacts important biometrics, such as glucose levels and ...
    Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
    ... common and deadly form of primary malignant brain cancer ... occurring mostly in adults between the ages of 45 ... cancer is only temporarily contained by combined surgery, chemotherapy ... fatal, resulting in an average patient survival time of ...
    ... passing from hand to hand, falling on streets and sidewalks, ... and sends it to the shredder. Rather than destroying it, ... to prolong its life. The research, which appears in the ... save billions and minimize the environmental impact of banknote disposal. ...
    ... Previous studies have established that carbon binds to tiny mineral ... , researchers have shown that the surface of the minerals ... carbon binds to minerals that are just a few thousandths ... almost exclusively on rough and angular surfaces," explains Prof. Ingrid ...
    Cached Biology News:Stopping tumors in their path 2
    RABBIT ANTI HUMAN ATR (aa2122-2380) Immunogen: Human ATR peptide, amino acids 2122-2380...
    ...
    ... The SelectFX Alexa Fluor 488 Cytochrome c ... you need to detect cytochrome c in ... c primary antibody and an Alexa ... 488 dye exhibits bright green fluorescence that ...
    For the quantitative determination of canine Interleukin 10,(IL-10) concentrations in cell culture supernates, canine serum,and plasma....
    Biology Products: